Eli Lilly cuts price of weight-loss drug Zepbound for self-paying patients - MarketWatch
1. LLY cuts prices on Zepbound; adds 7.5mg and 10mg doses. Strategy aims to improve affordability. 2. Price reductions apply to 2.5mg at $349 and 5mg at $499 doses. Lower pricing targets self-paying patients. 3. The move receives praise from obesity advocates. It strengthens LLY's competitive positioning. 4. LLY competes with Novo Nordisk in GLP-1 therapies. Pricing adjustments may boost long-term market share.